Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
BIOXYTRAN, INC entered into Common Stock Closing Agreement with Triton Funds LP valued at Purchase of 1,612,903 shares for $500,000 (approx. $0.31 per share) (effective 2023-06-08).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Triton Funds LP
- Value
- Purchase of 1,612,903 shares for $500,000 (approx. $0.31 per share)
- Effective
- 2023-06-08
Exact text from the filing
On June 8, 2023, Bioxytran, Inc. (the “Company”) entered into a common stock closing agreement (the “Closing Agreement”) with Triton Funds LP (“Triton”). Pursuant to the Closing Agreement, subject to certain conditions set forth in the Closing Agreement, Triton will purchase one million six hundred twelve thousand nine hundred three (1,612,903) shares of the Company’s Common Stock for an amount of five hundred thousand dollars ($500,000), or $0.31 per share (the “Closing Price”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
BIOXYTRAN, INC entered into Amended Engagement Letter with WallachBeth Capital LLC valued at Brokerage of three notes totaling $1,165,000, with issuance of 800,000 warrants exercisable at $0.20 (effective 2023-05-08).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- WallachBeth Capital LLC
- Value
- Brokerage of three notes totaling $1,165,000, with issuance of 800,000 warrants exercisable at $0.20
- Effective
- 2023-05-08
Exact text from the filing
On May 8, 2023, Bioxytran, Inc. (the “Company”) signed an amended engagement letter (the “Engagement Agreement”) with WallachBeth Capital LLC (“WallachBeth”) to brokerage a deal for three (3) of Company’s outstanding Notes, for a total value of one million one hundred sixty-five thousand dollars ($1,165,000).
View on SEC.gov